Huapont Life Sciences Co Ltd
SZSE:002004
Intrinsic Value
Huapont Life Sciences Co., Ltd. engages in the manufacture of chemical raw materials. [ Read More ]
The intrinsic value of one
Huapont Life Sciences Co Ltd
stock under the Base Case scenario is
6.79
CNY.
Compared to the current market price of 4.44 CNY,
Huapont Life Sciences Co Ltd
is
Undervalued by 35%.
Huapont Life Sciences Co Ltd's market capitalization is 8.8B CNY.
Huapont Life Sciences Co Ltd stock price is 4.44 CNY.
Huapont Life Sciences Co Ltd stock price (4.44 CNY) is 35% less than its Intrinsic Value (6.79 CNY).
Huapont Life Sciences Co Ltd stock price (4.44 CNY) is 18% less than its DCF Value (5.41 CNY). Open DCF Valuation
Huapont Life Sciences Co Ltd stock price (4.44 CNY) is 46% less than its Relative Value (8.16 CNY). Open Relative Valuation
Huapont Life Sciences Co Ltd has upside potential of 170% compared to the average analyst price target.
Open Wall St Estimates
Huapont Life Sciences Co Ltd has positive Net Debt. This means that the company has more debt (9B CNY) than cash and short-term investments (4B CNY).
Huapont Life Sciences Co Ltd's short-term assets (11B CNY) exceed its short-term liabilties (10B CNY).
Huapont Life Sciences Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 6% to 3%.
Huapont Life Sciences Co Ltd has positive Operating Income for the last twelve months.
Huapont Life Sciences Co Ltd's Revenue has been growing by 4% per year for the last 3 years.
Huapont Life Sciences Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 7% to 2%.
Huapont Life Sciences Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
Huapont Life Sciences Co Ltd has positive Net Income for the last twelve months.
Huapont Life Sciences Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 2%.
Huapont Life Sciences Co Ltd has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
Huapont Life Sciences Co Ltd's Revenue has dropped by 14% over the past 12 months.
Huapont Life Sciences Co Ltd has positive Free Cash Flow for the last twelve months.
Huapont Life Sciences Co Ltd has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
Huapont Life Sciences Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.83.
Huapont Life Sciences Co Ltd's long-term assets (30B CNY) exceed its long-term liabilties (20B CNY).
Huapont Life Sciences Co Ltd has positive Gross Profit for the last twelve months.
Huapont Life Sciences Co Ltd's Altman Z-Score is very low and is equal to 1.05.
Valuation Backtest
Huapont Life Sciences Co Ltd
Run backtest to discover the historical profit from buying and selling
Huapont Life Sciences Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Huapont Life Sciences Co Ltd
Balance Sheet Decomposition
Huapont Life Sciences Co Ltd
| Current Assets | 11.2B |
| Cash & Short-Term Investments | 4.4B |
| Receivables | 2.8B |
| Other Current Assets | 4B |
| Non-Current Assets | 19.2B |
| Long-Term Investments | 3.7B |
| PP&E | 9.4B |
| Intangibles | 4.7B |
| Other Non-Current Assets | 1.4B |
| Current Liabilities | 10.4B |
| Accounts Payable | 1.2B |
| Accrued Liabilities | 291.4m |
| Short-Term Debt | 5.9B |
| Other Current Liabilities | 3B |
| Non-Current Liabilities | 9.7B |
| Long-Term Debt | 2.6B |
| Other Non-Current Liabilities | 7.1B |
Earnings Waterfall
Huapont Life Sciences Co Ltd
|
Revenue
|
11.9B
CNY
|
|
Cost of Revenue
|
-7.2B
CNY
|
|
Gross Profit
|
4.7B
CNY
|
|
Operating Expenses
|
-3.5B
CNY
|
|
Operating Income
|
1.2B
CNY
|
|
Other Expenses
|
-959.3m
CNY
|
|
Net Income
|
221.2m
CNY
|
Free Cash Flow Analysis
Huapont Life Sciences Co Ltd
Profitability Score
Profitability Due Diligence
Huapont Life Sciences Co Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Huapont Life Sciences Co Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Huapont Life Sciences Co Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Huapont Life Sciences Co Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Huapont Life Sciences Co Ltd
According to Wall Street analysts, the average 1-year price target for
Huapont Life Sciences Co Ltd
is 12 CNY
.
Shareholder Return
Price
Huapont Life Sciences Co Ltd
| Average Annual Return | 5.31% |
| Standard Deviation of Annual Returns | 28.04% |
| Max Drawdown | -58% |
| Market Capitalization | 8.8B CNY |
| Shares Outstanding | 1 979 644 300 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Huapont Life Sciences Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Huapont Life Sciences Co., Ltd. engages in the manufacture of chemical raw materials. The company is headquartered in Chongqing, Chongqing and currently employs 12,206 full-time employees. The company went IPO on 2004-06-25. The firm operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The firm is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
Huapont Life Sciences Co Ltd
stock under the Base Case scenario is
6.79
CNY.
Compared to the current market price of 4.44 CNY,
Huapont Life Sciences Co Ltd
is
Undervalued by 35%.
You don't have any saved screeners yet
